Prior to
publication of the final rule, the agency should provide to OMB a
summary of all comments received on the proposed information
collection and identify any changes made in response to these
comments.
Inventory as of this Action
Requested
Previously Approved
09/30/2020
36 Months From Approved
09/30/2020
57
0
57
7,330
0
7,330
0
0
0
The ICR describes the information
collection involved with the De Novo classification process for
medical devices. FDA uses the information in the De Novo request to
evaluate whether the medical device may be reclassified from Class
III to Class I or II, and if applicable, to determine the general
and/or special controls necessary to sufficiently regulate the
medical device. Respondents to the information collection are
medical device manufacturers.
Based on updated data and
trends since the previous approval, we expect to receive
approximately 60 De Novo requests per year; an increase of 8
respondents per year. There is no change to the currently approved
burden estimate for “Written notice of withdrawal” of a De Novo
request. However, we have updated the name of the IC to indicate
that it is now under proposed 860.267(a)(4). The revisions
described above increase the total burden estimate by 3,640
hours.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.